Arm Stock Falls After HSBC Downgrade, Citing Limited Near-Term AI Upside 
Apple Intelligence China Approval Lifts Alibaba and Baidu Shares 
SK Hynix Stock Soars as AI Memory Demand Outlook Fuels Chip Rally 
UBS Boosts China Tech Bets, Adds Kuaishou and Meituan to Focus List 
BHP Faces Major Port Hedland Strike as Labor Talks Stall Ahead of Production Report 
Alibaba Stock Jumps as China Approves Apple Intelligence Powered by Qwen AI 
Rio Tinto Reports Strong Q2 Iron Ore Sales, Maintains 2026 Production Outlook 
DeepSeek Eyes China IPO as AI Startup Seeks $71 Billion Valuation in New Funding Round 
Sodexo Unveils Shift & Grow 2030 Strategy, Targets Over 5% Revenue Growth by Fiscal 2030 
Hyundai Takes Full Control of Boston Dynamics to Accelerate Humanoid Robot and AI Strategy 
Stripe, Advent Offer Over $53 Billion to Acquire PayPal in Major Fintech Deal 
xAI Sues Man for Allegedly Using Grok to Generate AI Child Abuse Deepfakes 
Airbus Signs Cloud Deal With Scaleway to Power Secure AI and Defense Applications 
Taiwan Mangoes Head to Europe as Premium Fruit Exports Expand 
SEB Q2 Profit Rises on Strong Lending, Record Fee Income, Announces New Share Buyback 
DBS Targets S$1 Trillion Wealth AUM by 2030 Amid Asia Wealth Boom 
Jamie Dimon Warns Anthropic's Mythos AI Poses National Security Risks 
TEL AVIV, Israel, Feb. 01, 2016 -- VBL Therapeutics (NASDAQ:VBLT), announced today that Chief Executive Officer, Dror Harats, M.D., will provide a corporate overview and business update at the BIO CEO & Investor Conference.
| Presentation Details: | |
| Title: | The 18th Annual BIO CEO & Investor Conference |
| Date: | February 9th, 2016 |
| Time: | 11:30-11:55 AM |
| Location: | The Waldorf Astoria New York |
| Webcast: | http://www.veracast.com/webcasts/bio/ceoinvestor2016/47215257222.cfm |
About VBL
Vascular Biogenics Ltd., operating as VBL Therapeutics, is a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of first-in-class treatments for cancer. The company's lead oncology product candidate, VB-111, is a gene-based biologic that is initially being developed for recurrent glioblastoma (rGBM), an aggressive form of brain cancer. VB-111 has received orphan drug designation in both the United States and Europe and was granted Fast Track designation by the FDA for prolongation of survival in patients with glioblastoma that has recurred following treatment with standard chemotherapy and radiation. VBL Therapeutics' pivotal Phase 3 GLOBE trial of VB-111 in rGBM is ongoing under a special protocol assessment granted by the FDA.
INVESTOR CONTACT: Michael Rice, Founding Partner LifeSci Advisors, LLC 646-597-6979
